GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 6:00 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 6:00 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up
by Zacks Equity Research
Glaxo (GSK) beats both earnings and revenues in the second quarter of 2018, and signs a four-year collaboration with 23andMe and invests $300 million for the same.
Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit
by Zacks Equity Research
Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.
ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions
by Zacks Equity Research
The pharma/biotech industry has witnessed a solid start in the Q2 reporting cycle. Let's see if leading players - Merck (MRK) and AbbVie (ABBV) - can contribute further to the encouraging numbers.
Merck's Keytruda Improves Survival in Head/Neck Cancer Study
by Zacks Equity Research
Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phase III program. It is being evaluated for the first-line treatment of patients with advanced head and neck cancer.
Glaxo (GSK) Beats on both Earnings and Revenue in Q2
by Zacks Equity Research
Glaxo beat both earnings and sales estimates in the second quarter of 2018.
Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive second-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK
by Zacks Equity Research
The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.
Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Pharmaceuticals and Vaccines segments are likely to boost sales in Q2 earnings.
Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion
by Zacks Equity Research
Novartis' (NVS) breast cancer drug, Kisqali, gets FDA approval as first-line treatment for pre-, peri- or post-menopausal women with HR+/HER2- advanced breast cancer.
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
by Zacks Equity Research
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.
Is a Surprise in the Cards for Novartis in Q2 Earnings?
by Zacks Equity Research
Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.
Pfizer (PFE) to Reorganize Business Into Three New Units
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
by Zacks Equity Research
The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
PFE vs. GSK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. GSK: Which Stock Is the Better Value Option?
Novartis to Spin-Off Alcon as Separate Trading Company
by Zacks Equity Research
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
New Strong Sell Stocks for July 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
by Kinjel Shah
In the first six months of the year, the FDA grants approval to 17 new treatments.
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
by Zacks Equity Research
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
Will a Trade War With China Wreak Havoc in US Healthcare?
by Nitish Marwah
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel
by Zacks Equity Research
Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.
Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
by Zacks Equity Research
Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.
Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection
by Zacks Equity Research
Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.